Overview

Our T-cell therapy targeting the NY-ESO peptide, which is present across multiple cancer types, is partnered with GSK. Following option exercise, the NY-ESO program is being transferred to GSK during a transition period.

Our NY-ESO SPEAR T-cell has been used in multiple Phase 1/2 clinical trials in patients with solid tumors and haematological malignancies, including synovial sarcoma, myxoid round cell liposarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. We have seen responses and evidence of tumor reduction in patients with both synovial sarcoma and multiple myeloma.The initial data suggest a promising risk/benefit profile. Breakthrough therapy designation in the United States and PRIME regulatory access in Europe have been granted to the NY-ESO SPEART T-cell.

Read more about our strategic collaboration with GSK.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
NY-ESO TCR Synovial Sarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: High NY-ESO expression, 12 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 2: Low NY-ESO expression, 10 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 3: Removal of fludarabine, 5 patients 1
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 4: Modified CTX/fludarabine, 10 patients
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Myxoid Round Cell Liposarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Multiple Myeloma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Atuologous SCT, 25 patients.
Data published in N.Med.
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 2: Combination study: no auto JCT, 2 cohorts
Research Phase complete
Pre-IND Phase in progress
Phase 1/2 Phase not started
Ovarian GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: 10 patients, Modified CTX/fludarabine
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Melanoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
NSCLC GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: 10pts, Stage IIIb / IV NSCLC
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
NCI: Synovial Sarcoma/Myeloma Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: Complete
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
ATTACK: Esophageal Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress

Our Clinical Trials